Recursion Pharmaceuticals, Inc.RXRX
ASignal's systematic analysis rates RXRX as Neutral.
Reflects the latest available analysis · analyzed Sep 4, 2026
The case on RXRX
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Low debt-to-equity ratio (0.07x) indicating strong financial health
- High cash position ($545.68M) providing operational runway
- Current ratio of 5.03x suggesting strong liquidity position
- RSI near neutral (57.69), not overbought or oversold
- Severely negative operating margin (-1759.69%)
- Negative revenue growth (-60.10% YoY)
- Negative free cash flow (-$219.49M)
- Negative EV/EBITDA (-2.88x) and unprofitable operations
- Extremely high price-to-sales ratio (33.63x)
- No Reddit mentions, suggesting lack of retail investor interest
See the full verdict on RXRX
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes RXRX
Most investors never get a second opinion, let alone several. ASignal runs RXRX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.